Prof. O’ Driscoll is Associate Professor of Pharmacology and Director of Research at the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin, where she was elected to Fellowship in 2012. Upon completing her PhD, Prof. O’Driscoll worked on biotechnology/biomedical research studies for US and EU industry (incl. Berlex; Archport Ltd./Diosynth; Medi-Syn Ltd; Meda-Nova Ltd.) before returning to academic research and teaching. At Post-Doctoral level, Prof. O’Driscoll gained research experience at the Dana-Farber Cancer Institute, Harvard University and the University of Miami.

Prior to joining Trinity College Dublin, Prof. O’Driscoll most recently held a position of Senior Research Programme Leader in cancer, NICB & Lecturer in School of Biotechnology, DCU. The main focus of Prof. O’ Driscoll’s research group is on diagnostic and predictive companion biomarkers; new therapeutics and their targets; and mechanisms of cell-cell communication via exosomes and microvesicles conferring resistance to both classical chemotherapy and targeted molecules and supporting cancer metastasis in vitro and in vivo.

Prof. O’ Driscoll has received a number of awards including Proctor & Gamble Young Scientist, DCU’s Albert College Fellowship, Dublin City University’s Inaugural Research Fellowship and members of her research group have won the Pfizer Gold Medal in Pharmacology and the RAMI Barcroft Medal. The output from this team has included patents; publications; and cancer clinical trials, with generous funding support from Irish & European authorities incl. EU Framework Programmes (leading an FP7 COST action on Microvesicles and Exosomes in Health and Disease,; ME-HaD 2013-2017), Science Foundation Ireland, Health Research Board, Enterprise Ireland, Mater Foundation, Danish Strategic Research Council, HEA’s PRTLI, Irish Cancer Society, industry and philanthropy.